NasdaqCM - Delayed Quote USD

electroCore, Inc. (ECOR)

Compare
7.87 -0.08 (-1.01%)
At close: October 8 at 4:00 PM EDT
Loading Chart for ECOR
DELL
  • Previous Close 7.95
  • Open 7.95
  • Bid --
  • Ask --
  • Day's Range 7.51 - 8.07
  • 52 Week Range 4.90 - 8.08
  • Volume 24,387
  • Avg. Volume 14,292
  • Market Cap (intraday) 50.737M
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) -2.05
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

www.electrocore.com

68

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ECOR

View More

Performance Overview: ECOR

Trailing total returns as of 10/8/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ECOR
32.22%
S&P 500
20.57%

1-Year Return

ECOR
40.79%
S&P 500
33.48%

3-Year Return

ECOR
49.06%
S&P 500
30.71%

5-Year Return

ECOR
79.51%
S&P 500
95.70%

Compare To: ECOR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ECOR

View More

Valuation Measures

Annual
As of 10/8/2024
  • Market Cap

    50.74M

  • Enterprise Value

    40.48M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.42

  • Price/Book (mrq)

    4.42

  • Enterprise Value/Revenue

    1.90

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -66.84%

  • Return on Assets (ttm)

    -49.18%

  • Return on Equity (ttm)

    -153.49%

  • Revenue (ttm)

    21.28M

  • Net Income Avi to Common (ttm)

    -14.22M

  • Diluted EPS (ttm)

    -2.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.23M

  • Total Debt/Equity (mrq)

    34.63%

  • Levered Free Cash Flow (ttm)

    -6.56M

Research Analysis: ECOR

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 6.14M
Earnings -2.65M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: ECOR

People Also Watch